• Medical_Professionals
• Medical_students
• Nurses

The development of immunotherapies to treat cancer has transformed the way clinicians think about managing their patients with many forms of malignancies. The speed at which basic science and clinical trial information continue to emerge in this area, however, creates practice and/or educational gaps for busy clinicians who strive to maintain state-of-the art care for their patients with cancer. This field is one of the most clinically relevant and exciting areas of novel drug development in oncology.

“But how do I use this information to manage my patients with cancer?”

This is the key question, and the one whose answer ultimately means the most to your patients. The 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application will do just that, by answering that question. This exciting and fast-paced Congress will provide a multi-module curriculum-based program that focuses exclusively on immunotherapies and their application to the management of cancer. This intensive, 1-day interactive program will provide a comprehensive review of the key data sets that are most relevant to the application of these novel strategies for the clinician who manages some of the most difficult-to-treat forms of cancer. The program will focus on the practical application of recent clinical trial results that have shaped current and evolving clinical management, evolving biomarker information, the latest basic science findings, and the most highly anticipated clinical trials in the field.

Target Audience

This educational program is directed toward oncologists, nurses, and pharmacists. Participants will be primarily those whose practice requires mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on immunotherapies and their evolving roles in the treatment of cancer.

Learning Objectives

After completing this educational activity, the participants will be able to:

Explain current and evolving mechanistic approaches concerning how the immune system can be targeted in the treatment of cancer.

Evaluate clinical trial findings on immuno-oncology strategies and how they can be practically applied to the management of cancer in multiple lines of care.

Discuss emerging methods to personalize care via the use of biomarkers and other methods to individualize the use of immuno-oncology strategies.

Describe how common and uncommon adverse events, associated with the use of immuno-oncology strategies, can be proactively mitigated and managed.

Detail important remaining clinical questions in the field, and highly anticipated ongoing clinical trials, that are evaluating emerging immuno-oncology strategies.

Arjun V. Balar, MD

Director of GU Medical Oncology, Laura and Isaac Perlmutter Cancer Center

Assistant Professor

NYU Langone Medical Center

New York, NY

Julie Brahmer, MD

Co-Director of the Upper Aerodigestive Department within the Bloomberg~Kimmel Institute for Cancer Immunotherapy

Associate Professor of Oncology

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Baltimore, MD

Charles Drake, MD, PhD

Professor of Oncology and Immunology

Director, Genitourinary Cancer Program

Co-director of the Immunotherapy Program

Herbert Irving Comprehensive Cancer Center

Columbia University Medical Center

New York, New York, USA

Dung Le, MD

Associate Professor of Oncology

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Baltimore, MD

David F. McDermott, MD

Associate Professor, Medicine

Harvard Medical School

Staff Physician, Hematology/Oncology

Director, Biologic Therapy and Cutaneous Oncology Programs, Hematology/Oncology

Beth Israel Deaconess Medical Center

Boston, MA

David L. Porter, MD

Jodi Fisher Horowitz Professor in Leukemia Care Excellence

Director, Blood and Marrow Transplantation

Hospital of the University of Pennsylvania

Philadelphia, PA

Michael A. Postow, MD

Medical Oncologist

Memorial Sloan Kettering Cancer Center

New York, NY

Tanguy Y. Seiwert, MD 

Medical Oncologist

The University of Chicago Medicine

Chicago, IL

Janice M. Taube, MD

Director of Dermatopathology Division and Fellowship

Associate Professor of Dermatology, Pathology, and Oncology

Johns Hopkins University SOM

Baltimore, MD

Jeffrey S. Weber, MD, PhD

Deputy Director

Laura and Isaac Perlmutter Cancer Center

Professor of Medicine

NYU Langone Medical Center

New York, NY

E. John Wherry, PhD

Director, Institute for Immunology

Professor, Microbiology

University of Pennsylvania

Philadelphia, PA

AUD

Group registrations not allowed

Accompanying persons not allowed

We don’t accept Online Abstracts

InterContinental New York Times Square

300 W 44th St, New York, NY 10036

Phone: (212) 803-4500

Be sure to mention the 2nd Annual International Congress on Immunotherapies in Cancer when making reservations to receive the discounted rate.

Location

The InterContinental New York Times Square is located near Grand Central Station. It is also conveniently located near La Guardia Airport (LGA), John F. Kennedy Airport (JFK), and Newark Liberty International Airport (EWR).

Room Rates

All room rates are subject to applicable state and local taxes.

Superior King | Double: $479 (single/double rate).

The deadline for making your discounted hotel reservations is November 10, 2017. After that date, or in the event that the room block becomes full prior to the deadline, rooms are subject to availability and the room rates may increase.

Submission Info

Physicians' Education Resource, LLC

Phone: 609-378-3701

Fax: 609-257-0705

Email: info@gotoper.com

Physicians' Education Resource, LLC

Phone: 609-378-3701

Fax: 609-257-0705

Email: info@gotoper.com